WO2025257768 - IMIDAZOLIUM-BASED CATIONIC LIPID FOR DELIVERY OF NUCLEIC ACID
National phase entry is expected:
Publication Number
WO/2025/257768
Publication Date
18.12.2025
International Application No.
PCT/IB2025/055992
International Filing Date
11.06.2025
Title **
[English]
IMIDAZOLIUM-BASED CATIONIC LIPID FOR DELIVERY OF NUCLEIC ACID
[French]
LIPIDE CATIONIQUE À BASE D'IMIDAZOLIUM POUR L'ADMINISTRATION D'ACIDE NUCLÉIQUE
Applicants **
WELGENE INC
Inventors
CHAN-PARK, Mary
JIE, Ooi, Ying
PARK, Jong, Gu
KIM, Gyung, Woo
PHELAN, John, Christopher
Priority Data
63/659,187
12.06.2024
US
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| Number of Office Actions | * |
| * | |
International Searching Authority |
MOIP
* |
| Recordal of a Change of the Applicant's Name/Address |
Change of Applicant's Name and Address
* |
| Type of Assignment |
The Standard Agent's Assignment
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Patent Delivery |
Send the Letters Patent by Courier
* |
| 译文 |
|
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing, Examination, Granting | 2846 | |
| EPO | Filing, Examination, Granting | 23156 | |
| Japan | Filing, Examination, Granting | 2833 | |
| South Korea | Filing, Examination, Granting | 2578 | |
| USA | Filing, Examination, Granting | 12340 |
Total:
43,753
Contact Us
Abstract[English]
Disclosed are imidazolium-based cationic lipid useful for non-viral delivery of nucleic acids. These imidazolium-based cationic lipid that can be formulated into lipid nanoparticle and encapsulated nucleic acid, such as small interfering RNA (siRNA) and messenger RNA (mRNA). The disclosure not only provides efficient siRNA delivery and excellent gene silencing, but also able to mediate mRNA translation to produce proteins of interest.[French]
L'invention concerne un lipide cationique à base d'imidazolium utile pour l'administration non virale d'acides nucléiques. Ces lipides cationiques à base d'imidazolium peuvent être formulés sous forme de nanoparticule lipidique et sous forme d'acide nucléique encapsulé, tel qu'un petit ARN interférent (ARNsi) et un ARN messager (ARNm). La divulgation concerne non seulement une administration efficace d'ARNsi et un excellent silençage génique, mais est également apte à médier la traduction d'ARNm pour produire des protéines d'intérêt.